Trois-Rivières

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• COPD7 trials
• Heart failure4 trials
• Lung cancer2 trials
• Asthma1 trial
• Bronchiectasis1 trial
• Chronic rhinosinusitis with nasal polyps1 trial
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Idiopathic pulmonary fibrosis1 trial
• Obesity1 trial
• Rheumatoid arthritis1 trial
• Type 2 diabetes1 trial

Phase

• Phase 312 trials
• Phase 27 trials
• Phase 2/31 trial

Status

• Recruiting9 trials
• Completed7 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• AstraZeneca19 trials
• DalCor Pharmaceuticals1 trial
• Endeavor Biomedicines, Inc.1 trial

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  NCT07784270· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

  NCT07000136· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  NCT06357533· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

  NCT05984277· Phase 3· AstraZeneca· Source

• Recruiting

  Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT05918861· Phase 3· DalCor Pharmaceuticals· Source

  Contact: David Kallend, MBBS

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD3 recruiting
• Heart failure3 recruiting
• Coronary artery disease1 recruiting
• Lung cancer1 recruiting
• Obesity1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07088926· Phase 2· AstraZeneca· Source

• Completed

  An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

  NCT05492877· Phase 2· AstraZeneca· Source

• Completed

  A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT05573464· Phase 3· AstraZeneca· Source

• Completed

  Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

  NCT04986202· Phase 2/3· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

  NCT04851964· Phase 3· AstraZeneca· Source

• Completed

  A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

  NCT04631016· Phase 2· AstraZeneca· Source

• Completed

  Tezepelumab COPD Exacerbation Study

  NCT04039113· Phase 2· AstraZeneca· Source

• Completed

  Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

  NCT03833141· AstraZeneca· Source